Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): Extension Study
2010-023650-36Phase 3Completed
- Sponsor
- Helsinn Therapeutics (U.S.), Inc.
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anamorelin in non-small cell lung cancer (NSCLC) and cancer anorexia-cachexia syndrome (CACS), sponsored by Helsinn Therapeutics (U.S.), Inc. Primary endpoints: Change in body weight from original trial baseline and Safety and tolerability. Started Jun 2011; status: completed.
02
Drugs
anamorelin
03
Conditions
non-small cell lung cancer (NSCLC)cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on 2010-023650-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023650-36.